Li-McLeod J, Perfetto E M
Bayer Corporation, West Haven, Connecticut, USA.
Manag Care Interface. 2001 Feb;14(2):52-9.
Past research on acute exacerbation of chronic bronchitis (AECB) has not quantified related work loss. This exploratory study used data from a comparative trial of moxifloxacin versus levofloxacin to examine and compare workplace-related indirect costs. Both groups reported considerable absenteeism and lowered work productivity. However, patients taking moxifloxacin reported significantly higher work productivity than those taking levofloxacin (70% vs. 50%; P = .03). This translated into substantial indirect cost savings with moxifloxacin of $726/patient/year. Antibiotic choice in AECB can affect worker productivity and workplace-related indirect costs. Both insurers and employers should consider workplace-related indirect costs in addition to direct medical expenses when making formulary selections.
过去对慢性支气管炎急性加重（AECB）的研究未对相关工作损失进行量化。这项探索性研究使用了莫西沙星与左氧氟沙星对比试验的数据，以检查和比较与工作场所相关的间接成本。两组均报告了相当多的旷工情况以及工作效率降低。然而，服用莫西沙星的患者报告的工作效率显著高于服用左氧氟沙星的患者（70%对50%；P = .03）。这意味着使用莫西沙星可使每位患者每年间接成本大幅节省726美元。AECB治疗中抗生素的选择会影响员工生产力和与工作场所相关的间接成本。保险公司和雇主在进行处方选择时，除了直接医疗费用外，都应考虑与工作场所相关的间接成本。
